Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf088 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Bernard Ngara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Linezolid, Diarylquinolines, Antitubercular Agents, Nitroimidazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swiss State Secretariat for Education, Research, and Innovation, Bavarian Ministry for Science, German Center for Infection Research.
Abstract (Originalsprache)
Background
BTZ-043 is a promising novel drug candidate for antituberculosis treatment. This study aimed to apply a previously developed mouse-to-human translational modeling platform for antituberculosis drugs to predict phase 2A outcomes for BTZ-043 in humans and evaluate the impact of observed drug-drug interactions on the contribution of BTZ-043 to combotherapy in a mouse model.
Methods
The study utilized data from mouse experiments for BTZ-043 monotherapy and combotherapy with bedaquiline, pretomanid, and linezolid, and clinical information for BTZ-043 monotherapy. The translational models were applied to predict the colony-forming units as a measure of efficacy in humans treated with BTZ-043 monotherapy and evaluate the effect of BTZ-043 on the pharmacokinetics-pharmacodynamics of combotherapy bedaquiline, pretomanid, and linezolid.
Results
The mouse-pharmacokinetic and mouse-pharmacodynamic data for BTZ-043 monotherapy were best described by 2-compartmental and direct Emax models, respectively. The model-based prediction of efficacy in humans was comparable to the observed phase 2A efficacy. Single-compartmental models, developed separately, best described the mouse-pharmacokinetic data for bedaquiline, pretomanid, and linezolid in combotherapy. Coadministration with BTZ-043 was associated with at least a 2-fold reduction in bedaquiline, pretomanid, and linezolid exposures in mice, and model-based simulations suggested that the observed decreases in exposure to these drugs would have resulted in even lower efficacy than what was observed when bedaquiline, pretomanid, and linezolid are coadministered with BTZ-043.
Conclusions
The translational modeling platform adequately predicted the efficacy of BTZ-043 monotherapy. In the absence of drug-drug interactions, coadministration of BTZ-043 with bedaquiline, pretomanid, and linezolid in combotherapy is predicted to improve treatment efficacy. Clinical Trials Registration. NCT0404400.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.
- Center for Tuberculosis, University of California, San Francisco, California, USA.
- Department of Pharmacy, University of Pisa, Pisa, Italy.
- Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Division of Infection Immunology, Research Center Borstel-Leibniz Lung Center, Borstel, Germany.
- Thematic Translational Unit Tuberculosis, German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
ORCID-Profile: Bernard Ngara, Lorenzo Flori, Rob Christiaan van Wijk, Jacqueline P Ernest, Sandeep Tyagi, Heena Soni, Kerstin Walter, Julia Dreisbach, Michael Hoelscher, Eric L Nuermberger, Radojka M Savic
Förderung
- Swiss State Secretariat for Education, Research, and Innovation
- Bavarian Ministry for Science
- German Center for Infection Research
- TB Alliance
- NIH HHS
- NIAID NIH HHS
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- German Ministry for Education and Research
Zitieren
APA
Ngara, B., Flori, L., van Wijk, R. C., Ernest, J. P., Tyagi, S., Soni, H., Hölscher, C., Walter, K., Dreisbach, J., Hoelscher, M., Nuermberger, E. L., & Savic, R. M. (2025). Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf088
Vancouver
Ngara B, Flori L, van Wijk RC, Ernest JP, Tyagi S, Soni H, et al. Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf088
BibTeX
@article{Ngara2025,
author = {Ngara, Bernard and Flori, Lorenzo and van Wijk, Rob Christiaan and Ernest, Jacqueline P and Tyagi, Sandeep and Soni, Heena and Hölscher, Christoph and Walter, Kerstin and Dreisbach, Julia and Hoelscher, Michael and Nuermberger, Eric L and Savic, Radojka M},
title = {Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf088}
}
EUVIMED